Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Comparison of the Pharmacokinetic Properties of Triamcinolone and Dexamethasone for Local Therapy of the Inner Ear.

Salt AN, Hartsock JJ, Hou J, Piu F.

Front Cell Neurosci. 2019 Jul 30;13:347. doi: 10.3389/fncel.2019.00347. eCollection 2019.

2.

Local Drug Delivery for the Treatment of Neurotology Disorders.

Piu F, Bishop KM.

Front Cell Neurosci. 2019 Jun 3;13:238. doi: 10.3389/fncel.2019.00238. eCollection 2019. Review.

3.

Dexamethasone and Dexamethasone Phosphate Entry into Perilymph Compared for Middle Ear Applications in Guinea Pigs.

Salt AN, Hartsock JJ, Piu F, Hou J.

Audiol Neurootol. 2018;23(4):245-257. doi: 10.1159/000493846. Epub 2018 Nov 29.

PMID:
30497073
4.

The Sustained-Exposure Dexamethasone Formulation OTO-104 Offers Effective Protection against Cisplatin-Induced Hearing Loss.

Fernandez R, Harrop-Jones A, Wang X, Dellamary L, LeBel C, Piu F.

Audiol Neurootol. 2016;21(1):22-9. doi: 10.1159/000441833. Epub 2016 Jan 21.

5.

The Sustained-Exposure Dexamethasone Formulation OTO-104 Offers Effective Protection against Noise-Induced Hearing Loss.

Harrop-Jones A, Wang X, Fernandez R, Dellamary L, Ryan AF, LeBel C, Piu F.

Audiol Neurootol. 2016;21(1):12-21. doi: 10.1159/000441814. Epub 2015 Dec 11.

PMID:
26655654
6.

OTO-201: nonclinical assessment of a sustained-release ciprofloxacin hydrogel for the treatment of otitis media.

Wang X, Fernandez R, Tsivkovskaia N, Harrop-Jones A, Hou HJ, Dellamary L, Dolan DF, Altschuler RA, LeBel C, Piu F.

Otol Neurotol. 2014 Mar;35(3):459-69. doi: 10.1097/MAO.0000000000000261.

7.

Identification of the antiarrhythmic drugs amiodarone and lorcainide as potent H3 histamine receptor inverse agonists.

Del Tredici AL, Ma JN, Piu F, Burstein ES.

J Pharmacol Exp Ther. 2014 Jan;348(1):116-24. doi: 10.1124/jpet.113.208892. Epub 2013 Nov 7.

PMID:
24204014
8.

[Methodology for determining the index of caring complexity (ICC):prospective observational study in a stroke unit].

Cavaliere B, Piu F, Di Matteo R.

Prof Inferm. 2012 Oct-Dec;65(4):208-17. Italian.

PMID:
23343874
9.

Perilymph pharmacokinetics of markers and dexamethasone applied and sampled at the lateral semi-circular canal.

Salt AN, Hartsock JJ, Gill RM, Piu F, Plontke SK.

J Assoc Res Otolaryngol. 2012 Dec;13(6):771-83. doi: 10.1007/s10162-012-0347-y. Epub 2012 Sep 12.

10.

Discovery of potential antipsychotic agents possessing pro-cognitive properties.

Lameh J, McFarland K, Ohlsson J, Ek F, Piu F, Burstein ES, Tabatabaei A, Olsson R, Bradley SR, Bonhaus DW.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Mar;385(3):313-23. doi: 10.1007/s00210-011-0702-2. Epub 2011 Nov 15.

PMID:
22083558
11.

Principles of inner ear sustained release following intratympanic administration.

Wang X, Dellamary L, Fernandez R, Ye Q, LeBel C, Piu F.

Laryngoscope. 2011 Feb;121(2):385-91. doi: 10.1002/lary.21370.

PMID:
21271594
12.

Distribution of dexamethasone and preservation of inner ear function following intratympanic delivery of a gel-based formulation.

Salt AN, Hartsock J, Plontke S, LeBel C, Piu F.

Audiol Neurootol. 2011;16(5):323-35. doi: 10.1159/000322504. Epub 2010 Dec 19.

13.

OTO-104: a sustained-release dexamethasone hydrogel for the treatment of otic disorders.

Piu F, Wang X, Fernandez R, Dellamary L, Harrop A, Ye Q, Sweet J, Tapp R, Dolan DF, Altschuler RA, Lichter J, LeBel C.

Otol Neurotol. 2011 Jan;32(1):171-9. doi: 10.1097/MAO.0b013e3182009d29.

PMID:
21099726
14.

Inverse agonist activity of steroidogenic factor SF-1.

Piu F, Del Tredici AL.

Methods Enzymol. 2010;485:245-59. doi: 10.1016/B978-0-12-381296-4.00014-2.

PMID:
21050921
15.

Pharmacokinetics of dexamethasone solution following intratympanic injection in guinea pig and sheep.

Wang X, Fernandez R, Dellamary L, Harrop A, Ye Q, Lichter J, Lau D, Lebel C, Piu F.

Audiol Neurootol. 2011;16(4):233-41. doi: 10.1159/000320611. Epub 2010 Oct 28.

PMID:
20980743
16.

Dose-dependent sustained release of dexamethasone in inner ear cochlear fluids using a novel local delivery approach.

Wang X, Dellamary L, Fernandez R, Harrop A, Keithley EM, Harris JP, Ye Q, Lichter J, LeBel C, Piu F.

Audiol Neurootol. 2009;14(6):393-401. doi: 10.1159/000241896. Epub 2009 Nov 16.

PMID:
19923809
17.

Synthesis, structure-activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators.

Schlienger N, Lund BW, Pawlas J, Badalassi F, Bertozzi F, Lewinsky R, Fejzic A, Thygesen MB, Tabatabaei A, Bradley SR, Gardell LR, Piu F, Olsson R.

J Med Chem. 2009 Nov 26;52(22):7186-91. doi: 10.1021/jm901149c.

PMID:
19856921
18.

Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.

Pettersson H, Bülow A, Ek F, Jensen J, Ottesen LK, Fejzic A, Ma JN, Del Tredici AL, Currier EA, Gardell LR, Tabatabaei A, Craig D, McFarland K, Ott TR, Piu F, Burstein ES, Olsson R.

J Med Chem. 2009 Apr 9;52(7):1975-82. doi: 10.1021/jm801534c.

PMID:
19338356
19.

Design, synthesis, and structure-activity analysis of isoform-selective retinoic acid receptor beta ligands.

Lund BW, Knapp AE, Piu F, Gauthier NK, Begtrup M, Hacksell U, Olsson R.

J Med Chem. 2009 Mar 26;52(6):1540-5. doi: 10.1021/jm801532e.

PMID:
19239230
20.

Chemical genomics: massively parallel technologies for rapid lead identification and target validation.

Hacksell U, Nash N, Burstein ES, Piu F, Croston G, Brann MR.

Cytotechnology. 2002 Jan;38(1-3):3-10. doi: 10.1023/A:1021169023731.

21.

Identification of novel selective V2 receptor non-peptide agonists.

Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F.

Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12.

PMID:
18761325
22.

Differential modulation of inflammatory pain by a selective estrogen receptor beta agonist.

Gardell LR, Hyldtoft L, Del Tredici AL, Andersen CB, Fairbairn LC, Lund BW, Gustafsson M, Brann MR, Olsson R, Piu F.

Eur J Pharmacol. 2008 Sep 11;592(1-3):158-9. doi: 10.1016/j.ejphar.2008.06.107. Epub 2008 Jul 4.

PMID:
18644363
23.

Broad modulation of neuropathic pain states by a selective estrogen receptor beta agonist.

Piu F, Cheevers C, Hyldtoft L, Gardell LR, Del Tredici AL, Andersen CB, Fairbairn LC, Lund BW, Gustafsson M, Schiffer HH, Donello JE, Olsson R, Gil DW, Brann MR.

Eur J Pharmacol. 2008 Aug 20;590(1-3):423-9. doi: 10.1016/j.ejphar.2008.05.015. Epub 2008 May 23.

PMID:
18559275
24.

Pharmacological characterization of AC-262536, a novel selective androgen receptor modulator.

Piu F, Gardell LR, Son T, Schlienger N, Lund BW, Schiffer HH, Vanover KE, Davis RE, Olsson R, Bradley SR.

J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):129-37. doi: 10.1016/j.jsbmb.2007.11.001. Epub 2007 Nov 22.

PMID:
18164613
25.

Identification of the first synthetic steroidogenic factor 1 inverse agonists: pharmacological modulation of steroidogenic enzymes.

Del Tredici AL, Andersen CB, Currier EA, Ohrmund SR, Fairbain LC, Lund BW, Nash N, Olsson R, Piu F.

Mol Pharmacol. 2008 Mar;73(3):900-8. Epub 2007 Nov 30.

PMID:
18055761
26.

Monitoring interactions between receptor tyrosine kinases and their downstream effector proteins in living cells using bioluminescence resonance energy transfer.

Tan PK, Wang J, Littler PL, Wong KK, Sweetnam TA, Keefe W, Nash NR, Reding EC, Piu F, Brann MR, Schiffer HH.

Mol Pharmacol. 2007 Dec;72(6):1440-6. Epub 2007 Aug 22.

PMID:
17715395
27.

Pharmacology and signaling properties of epidermal growth factor receptor isoforms studied by bioluminescence resonance energy transfer.

Schiffer HH, Reding EC, Fuhs SR, Lu Q, Piu F, Wong S, Littler PL, Weiner DM, Keefe W, Tan PK, Nash NR, Knapp AE, Olsson R, Brann MR.

Mol Pharmacol. 2007 Feb;71(2):508-18. Epub 2006 Sep 12.

PMID:
16968809
28.

Integrative functional assays, chemical genomics and high throughput screening: harnessing signal transduction pathways to a common HTS readout.

Burstein ES, Piu F, Ma JN, Weissman JT, Currier EA, Nash NR, Weiner DM, Spalding TA, Schiffer HH, Del Tredici AL, Brann MR.

Curr Pharm Des. 2006;12(14):1717-29.

PMID:
16712484
29.

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.

Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE.

J Pharmacol Exp Ther. 2006 May;317(2):910-8. Epub 2006 Feb 9.

PMID:
16469866
30.

Identification of novel subtype selective RAR agonists.

Piu F, Gauthier NK, Olsson R, Currier EA, Lund BW, Croston GE, Hacksell U, Brann MR.

Biochem Pharmacol. 2005 Dec 19;71(1-2):156-62. Epub 2005 Nov 21.

PMID:
16303118
31.

Discovery of a potent, orally available, and isoform-selective retinoic acid beta2 receptor agonist.

Lund BW, Piu F, Gauthier NK, Eeg A, Currier E, Sherbukhin V, Brann MR, Hacksell U, Olsson R.

J Med Chem. 2005 Dec 1;48(24):7517-9.

PMID:
16302793
32.
33.

[Open letter to nurses and technicians working in cardiac rehabilitation].

Nicola L, Piu F.

Monaldi Arch Chest Dis. 2003 Jun;60(2):174. Italian. No abstract available.

PMID:
12918174
34.
35.

AP-1 repressor protein JDP-2: inhibition of UV-mediated apoptosis through p53 down-regulation.

Piu F, Aronheim A, Katz S, Karin M.

Mol Cell Biol. 2001 May;21(9):3012-24.

36.

The mammalian UV response: c-Jun induction is required for exit from p53-imposed growth arrest.

Shaulian E, Schreiber M, Piu F, Beeche M, Wagner EF, Karin M.

Cell. 2000 Dec 8;103(6):897-907.

37.

Control of cell cycle progression by c-Jun is p53 dependent.

Schreiber M, Kolbus A, Piu F, Szabowski A, Möhle-Steinlein U, Tian J, Karin M, Angel P, Wagner EF.

Genes Dev. 1999 Mar 1;13(5):607-19.

38.
39.

In vitro transforming capacities of mouse c-jun:junD chimeric genes.

Métivier C, Piu F, Pfarr CM, Yaniv M, Loiseau L, Castellazzi M.

Oncogene. 1993 Aug;8(8):2311-5.

PMID:
8336952
40.

Transforming growth factor beta 1-mediated growth inhibition in chick embryo fibroblasts: reversion by virally-expressed nuclear oncogenes.

Piu F, Jurdic P, Brun G, Samarut J, Castellazzi M.

C R Acad Sci III. 1993 Aug;316(8):772-9.

PMID:
8044700
41.

Chimeric c-Jun containing an heterologous homodimerization domain transforms primary chick embryo fibroblasts.

Castellazzi M, Loiseau L, Piu F, Sergeant A.

Oncogene. 1993 May;8(5):1149-60.

PMID:
8479740
42.

Overexpression of c-jun, junB, or junD affects cell growth differently.

Castellazzi M, Spyrou G, La Vista N, Dangy JP, Piu F, Yaniv M, Brun G.

Proc Natl Acad Sci U S A. 1991 Oct 15;88(20):8890-4.

Supplemental Content

Support Center